Marvel Biosciences Corp (TSE:MRVL) has released an update.
Marvel Biosciences Corp. has reported encouraging early results from a study of their new autism treatment, MB-204, which successfully normalized social behavior in mouse models with just a single oral dose. Developed by Marvel’s subsidiary, Marvel Biotechnology Inc., MB-204 has shown promising potential in addressing core symptoms of autism, sparking interest in its upcoming tests on other autism models. The company is known for its ‘drug redevelopment’ strategy, focusing on creating new derivatives of off-patent drugs to expedite development and reduce risks.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.
